Page 1 of 2 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Judith A. Boice, et al. Case No.: 21294P

Appl. No.: 10/559,676 Art Unit: 1612

Filed: December 7, 2005 Examiner: S. E. Clark

For: Use of Selective Cyclooxygenase-2 Inhibitors for the Treatment of Endometriosis

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

In compliance with 37 C.F.R. 1.97, submitted on the attached form PTO/SB/08a is a list of patents, publications, applications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication, application or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Pursuant to 37 C.F.R. 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

Applicants respectfully request the Examiner initial the attached form PTO/SB/08a after reviewing the pertinence of each reference.

Page 2 of 2 PATENT

INFORMATION DISCLOSURE STATEMENT

Any fees required in connection with this submission may be charged to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By: /Maria V. Marucci, Reg # 59895/

Maria V. Marucci Reg. No. 59,895

Attorney for Applicant(s)

MERCK & CO., INC. P.O. Box 2000

Rahway, N.J. 07065-0900

(732) 594-1637

Date: April 14, 2010